Affiliation:
1. Clinical Centre University in Sarajevo
2. Clinical Centre University of Sarajevo
3. University of Sarajevo
Abstract
<p><strong>Aim</strong> <br />Lung adenocarcinoma (ADC) is a leading subtype of lung cancer, histologically defined with five different architectural<br />growth patterns: lepidic, acinar, papillary, solid and micropapillary. The aim of this study was to explore the prevalence of epidermal growth factor receptor (EGFR) mutation and a relationship between the specific histological patterns of lung ADC in the population of Bosnia and Herzegovina.<br /><strong>Methods <br /></strong>The study included tumour tissue from 102 patients with completely resected lung ADC from 2015 to 2020. Molecular testing for the presence of EGFR mutations was performed by real-time PCR method. The relationship between EGFR mutation status and clinicopathological parameters was analysed.<br /><strong>Results</strong> <br />The EGFR mutation was detected in 12 (11.8%) cases of ADC, more often in non-smokers (p=0.007). A higher percentage<br />of solid growth pattern presented in ADC may be an indicator of EGFR negativity (p=0.039), while a higher percentage of micropapillary growth pattern more common in the presence of EGFR mutation (p=0.047).<br /><strong>Conclusion</strong> <br />The prevalence of EGFR mutation is in accordance with the expected prevalence considering our studied population,<br />Caucasians from South Europe. Better understanding of the relationship between histological patterns and molecular characteristics of lung ADC will enable earlier diagnosis and optimal treatment for patients.</p>
Publisher
Medical Association of Zenica-Doboj
Reference44 articles.
1. Global Cancer Observatory: Cancer Today;J.Ferlay,2020
2. World Cancer Research Fund International. Lung cancer statistics,2023-02-16
3. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart;W.D.Travis,2015
4. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology;N.I.Lindeman;J Thorac Oncol,2013
5. Oncogenic driver mutations in non-small cell lung cancer: past, present and future;M.Chevallier;World J Clin Oncol,2021